Congress caps insulin at $35—but only for the insured

What it does

This bill caps insulin cost-sharing at $35 per 30-day supply (or 25% of negotiated price, whichever is lower) for people with health insurance, effective January 1, 2026. It applies to group plans, individual coverage, and catastrophic plans, and requires insurers to cover at least one insulin product in each dosage form and type. The cap does not apply to out-of-network providers or non-selected insulin products.

Why we flagged it

The bill's core mechanism is a straightforward price ceiling on insulin cost-sharing across multiple insurance frameworks (PHSA, IRC, ERISA). It is consumer-protection legislation, not a tax measure, subsidy, or deregulation.

What the text implies

• Insurers may respond by narrowing formularies or raising premiums on other drugs to offset insulin losses, shifting costs elsewhere in the health system.
• The $35 cap applies only to 'selected' insulin products chosen by the plan, not all insulins—plans retain discretion to limit choice and may steer patients toward cheaper formulations.
• Out-of-network insulin is explicitly excluded, potentially creating access gaps for patients in rural areas or with limited in-network options.
• The bill does not address manufacturer list prices or rebate structures, so pharmaceutical companies may maintain high nominal prices while insurers absorb the cap via negotiation.

Who it affects

Millions of Americans with diabetes will face lower out-of-pocket costs for insulin, a life-sustaining medication. The $35 cap directly reduces financial barriers to access and may prevent rationing or skipping doses due to cost.

Who stands to gain

• insulin-dependent patients (direct)
• pharmacy benefit managers (may gain negotiating leverage)
• health insurers (may benefit from reduced claims if patients use more insulin due to affordability)

Named in the bill

PHSA (Public Health Service Act), IRC (Internal Revenue Code), ERISA (Employee Retirement Income Security Act), ACA (Patient Protection and Affordable Care Act), Biologics Price Competition and Innovation Act of 2009, FDA (implied, via section 351 licensure), group health plans, health insurance issuers, pharmacy benefit managers

Where it stands

11 cosponsors: 11 Democrats.

• Nov 21, 2025 — Introduced · Congress.gov: “Introduced in House”
• Nov 21, 2025 — Referred to House Committee on Education and Workforce and House Committee on Ways and Means · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.